Shan Shan Suo, Rong Feng Fu, Albert Qin, Zong Hong Shao, Jie Bai, Su Ning Chen, Ming Hui Duan, Hu Zhou, Na Xu, Su Jiang Zhang, Xue Lan Zuo, Xin Du, Li Wang, Pei Li, Xu Han Zhang, Dao Xiang Wu, Ya Ning Li, Jing Jing Zhang, Wei Wang, Wei Hong Shen, Oleh Zagrijtschuk, Toshiaki Sato, Zhi Jian Xiao, Jie Jin
BACKGROUND: Polycythemia vera (PV) is a myeloproliferative neoplasm. Ropeginterferon alfa-2b is a new-generation polyethylene glycol-conjugated proline-interferon. It is approved for the treatment of PV at a starting dose of 100 µg (50 µg for patients receiving hydroxyurea (HU)) and dose titrations up to 500 µg by 50 µg increments. The study was aimed at assessing its efficacy and safety at a higher starting dose and simpler intra-patient dose escalation. METHODS: Forty-nine patients with PV having HU intolerance from major hospitals in China were treated biweekly with an initial dose of 250 µg, followed by 350 µg and 500 µg thereafter if tolerated...
April 2024: Journal of Hematology (Brossard, Quebec)